Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately one in 15,000 people – about 500,000 individuals worldwide. Symptoms include, but are not limited to: delayed developmental milestones; gross and fine motor impairment; difficulty with feeding and swallowing; issues; loss of functional speech and epilepsy.
Angelman syndrome has been reversed multiple ways in mice, clincal trials are recruiting, and the progress scientists are making is thrilling.
There are currently three clinical trials recruiting in Australia at Melbourne, Sydney and Brisbane sites.
For more information visit
Australian Clinical Trials
Parents of children with Angelman Syndrome, who know what a diagnosis like this is like, are standing by to answer your questions and assist you.
FAST has a vision of a world where lives are no longer limited by a diagnosis of Angelman syndrome.
The mission of the Foundation for Angelman Syndrome Therapeutics Australia is to improve the quality of life for individuals with Angelman syndrome through timely diagnosis, access to best practices in care and treatments, and advancing research for a cure.
Founded in the United States, Australia is just one of the Global affiliates advancing Angelman syndrome research and clinical trials. FAST also has affiliates in Canada, France, Italy, Latin America (Argentina, Chile, Colombia), Spain and the UK.
Join our annual fundraising campaig
n, Cure Angelman Now!
As diverse as our Angelman community is, we are all united in one goal: a better future for our children. FAST is committed to bringing life-changing treatments to all individuals with Angelman syndrome, but we need your help!
